CCND2 and neoplasm: In only 59 % (10/17), 53 % (9/17), 41 % (7/17), 38 % (6/16) and 35 % (6/17) of the tumor samples, RASSF1A, HIN-1, MGMT, DAPK1 and CCND2 promoters showed methylation status ≥ LOQ.